Simon Baker

Simon Baker has an extensive work experience spanning over several companies and roles. Simon started their career as a Process Chemist at Rhone-Poulenc Rorer in 1992, where they worked until 1993. Simon returned to Rhone-Poulenc Rorer as a summer intern in 1994 and 1995. In 1996, Simon joined Imperial College London, where they pursued a PhD in Organic Chemistry until 2000.

After completing their education, Simon moved into the finance industry and joined Lehman Brothers in 2000. At Lehman Brothers, they served as the Executive Director, Healthcare Specialist Sales, and Head of European Healthcare Equities. Their responsibilities included equity research, IPO execution, and managing European Healthcare Equities. Simon remained with the company until 2008.

Simon joined Credit Suisse in 2009 as the Director of Healthcare Equity Sales, a role they held until 2011. Subsequently, they joined Occitan Capital Partners as a Healthcare Analyst, where they conducted detailed analysis of companies and specialized in event-based trading ideas and value- and growth-based investing. Simon worked at Occitan Capital Partners until 2013.

In 2013, Simon moved to Oriel Securities, where they served as a Partner and Biotech Specialist Sales. Simon then joined Exane in 2014 as an Executive Director in Pharmaceutical Equity Research. Their role involved research and analysis of pharmaceutical companies. Simon worked at Exane until 2019.

Currently, Simon is employed at Redburn, where they hold the position of Partner and Head of Global Biopharma Research since March 2019. Their work mainly revolves around research and analysis of the global biopharmaceutical industry.

Simon Baker attended Stamford School from 1984 to 1992, although no specific degree or field of study is mentioned. Simon then pursued higher education at Imperial College London from 1993 to 2000, earning a Ph.D. and a B.Sc. in Organic Chemistry. In 2004, they obtained a certification as a Chartered Financial Analyst (CFA) from the CFA Institute.